Associated Papers
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
Pisapia P et al.
Lung Cancer (amsterdam, Netherlands), 2024
Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma-An Indian Perspective of 212 Patients.
Kaler AK et al.
International Journal of Environmental Research and Public Health, 2022
Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma.
Salmani H et al.
Iranian Journal of Public Health, 2022
Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients.
Castellanos-Rizaldos E et al.
Oncotarget, 2019
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma.
Tian Y et al.
Plos One, 2018
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH et al.
Expert Review of Molecular Diagnostics, 2016
A primer and probe set for detecting multiple types of EGFR exon 19 deletions.
Chen TL et al.
Analytical Biochemistry, 2016
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
Paliogiannis P et al.
Molecular Medicine Reports, 2015
The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.
Xie G et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2015
Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A et al.
Diagnostic Pathology, 2014
Highly sensitive EGFR mutation detection by specific amplification of mutant alleles.
Leelatian N et al.
Experimental and Molecular Pathology, 2014
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM et al.
Journal of Cancer Research and Clinical Oncology, 2013
Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM et al.
American Journal of Clinical Pathology, 2013
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
Marchetti A et al.
Plos One, 2012
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Gu D et al.
Human Mutation, 2007
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Sequist LV et al.
The Oncologist, 2007